EpiBiologics is a San Mateo–based biotechnology company pioneering the degradation of disease-driving extracellular membrane and soluble proteins via its proprietary EpiTAC bispecific antibody platform. The company’s lead candidate, EPI-326, is designed to degrade all oncogenic forms of EGFR in a tumor-selective manner, aiming to overcome safety and resistance limitations of current EGFR therapies. Preclinical data show strong, durable efficacy with favorable safety and pharmacokinetic profiles, supporting both monotherapy and combination use across multiple cancer types. EpiBiologics plans to commence a first-in-human trial of EPI-326 in early 2026 for non-small cell lung cancer and head and neck squamous cell carcinoma. Proceeds from its recent financing will also expand a broader pipeline in oncology and immunology while bolstering internal capabilities. The company recently strengthened its leadership team by hiring Eric Humke, M.D., Ph.D., as Chief Medical Officer and Aaron Mishel as Chief Financial Officer, and added several industry leaders to its Board.

Total raised

$130M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2026